Saturday, March 2, 2024
HomeUncategorizedHeart disease will surge in coming decades

Heart disease will surge in coming decades

According to projections, millions of Americans are expected to suffer from cardiovascular disease (CVD) in the coming decades.

Cardiovascular disease patients are projected to increase substantially from 2025 to 2060, as demographics change:

  • Ischemic heart disease: 21.9 million to 28.7 million
  • Heart failure: 9.7 million to 12.9 million
  • Myocardial infarction: 12.3 million to 16 million
  • Stroke: 10.8 million to 14.5 million
  • In addition, by 2060, 54.6 million Americans will suffer from the disease, James Januzzi, MD, of Massachusetts General Hospital and Harvard Medical School in Boston, and colleagues report that 162.5 million Hypertension, 125.7 million people with dyslipidemia, and 125.7 million people with obesity.

    While the author is in Journal of the American College of Cardiology .

    The prevalence of cardiovascular (CV) risk factors and disease is projected to decrease by 2060 and increase in whites and in all other races and ethnicities. For example, among black adults, the estimated prevalence of diabetes, hypertension, dyslipidemia, and obesity would be 19.8%, 59.9%, 35.9%, and 45.6%, respectively.

    ” As Januzzi’s group wrote. ) “Emphasis on education about CV risk factors, improving access to quality health care, and promoting lower-cost access to treatment for CV risk factors Effective therapies may halt the rising trend of CV disease in high-risk populations; these advances need, however, to be applied in a more equitable manner throughout the United States,” they add.

    and Javed Butler, Medicine Ph.D., MPH, MBA, Dara Baylor University Medical Centers and University of Mississippi Medical Center in Jackson recommend that trends in deteriorating heart health can be controlled with appropriate targeted policies.

    Emphasizing the importance of CVD prevention for policy makers, noting that optimizing cardiovascular care teams and adjusting the training of future cardiologists, also pointed to staffing issues for healthcare workers during the COVID-19 pandemic Exacerbated.

    “In this series argues that training a workforce of physicians from diverse racial, ethnic and socioeconomic backgrounds could be a solid step towards better primary care and prevention efforts . However, recent data suggest that we still have a lot of work to do in this direction,” the two wrote.

    The study’s projections are based on the 2013-2018 National Health and Nutrition Examination Survey Data were pooled with 2020 U.S. Census projected counts from 2025 to 2060.

    Januzzi and colleagues acknowledge that their model assumes unchanged cardiovascular health patterns and that self-reported heart The disease data are reliable. In addition, the authors did not account for COVID-19 in their analysis.

    “Although these predictions have several assumptions, the significance of this work cannot be judged by the Overestimated,” Kalogeropoulos said in a press release. “Unless targeted action is taken, disparities in cardiovascular disease burden will only increase over time. ”

    • Nicole Lou is a reporter for MedPage Today covering cardiology news and other medical developments. Follow


    Januzzi report supported by Hutter Family Professorship; accepted Abbott Diagnostics, Applied Therapeutics, Innolife and Novartis Funding; receives consulting fees from Abbott Diagnostics, Boehringer Ingelheim, Janssen, Novartis, and Roche Diagnostics; participates in the Clinical Endpoints Committee/Data Safety Monitoring Committee of AbbVie, Siemens, Takeda, and Vifor; and is a Trustee and a Trustee of the American College of Cardiology Board member of Imbria Pharmaceuticals.

    Kalogeropoulos disclosed National Heart, Lung and Blood Institute, American Heart Association and CDC.

    Butler reported Abbott, Amgen , Regent, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, CVRx, G3 Pharmaceutical, Impulse Dynamics, Innolife, Janssen, LivaNova, Medtronic, Merck, Novartis, Novo Nordisk, Pfizer, Roche and Vifor.



Please enter your comment!
Please enter your name here


Featured NEWS